Quimi Daphne
Quimi Daphne's purchase track record
Quimi Daphne has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2024 | IPSC | $8K | -18.8% | -63.7% | -1.3% |
| 5/14/2024 | AMLX | $9K | +6.4% | +233.7% | +14.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Transaction History
| IPSC | ▲ Buy | Open Market | 5,000 | $8K | 9/12/2024 | View on chart |
| AMLX | ▲ Buy | Open Market | 2,250 | $4K | 5/15/2024 | View on chart |
| AMLX | ▲ Buy | Open Market | 2,750 | $5K | 5/14/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Century Therapeutics faces competitive pressure on key strategy
A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.
Century Therapeutics faces competitive pressure on key strategy. A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.